Global Fluorescence in situ hybridization probe Market
Global Fluorescence in situ hybridization probe Market

Fluorescence in situ hybridization probe Comprehensive Study by Type (RNA, DNA), Application (Cancer Diagnosis, Genetic Disorders, Others), End-User (Research Institutes, Diagnostic Centre, Biotechnology Companies, Companion Diagnostics, Academic Institutes), Technique (Q- FISH, Flow- FISH)

Fluorescence in situ hybridization probe Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 208 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Fluorescence in situ hybridization probe Market Scope?
It is a laboratory technique that is used for detecting a particular or a specific DNA or RNA sequence in the chromosome. The technique depends on exposing chromosomes to a tiny low DNA sequence known as a quest that encompasses a fluorescent module. It is one of the methods for localizing a piece of DNA within a genome that is called the Fluorescence in situ hybridization probe. The fluorescent dye is attached to a purified piece of DNA and then the DNA is incubated with a full set of chromosomes. The DNA is labeled which finds its matching pair in one of the chromosomes and sticks by it. By looking under the microscope the researcher can find the region where the DNA is bound because of the dye which is fluorescently attached to it.

The Fluorescence in situ hybridization probe market study is being classified by Type (RNA and DNA), by Application (Cancer Diagnosis, Genetic Disorders and Others) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that Players from United States will contribute to the maximum growth of Global Fluorescence in situ hybridization probe market throughout the predicted period.

Abbott Laboratories (United States), Abnova Corporation (Taiwan), Agilent Technologies (United States), Biocare Medical, LLC (United States), Biosearch Technologies Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Genemed Biotechnologies (United States), Life Science Technologies (India), Oxford Gene Technologies (United Kingdom) and PerkinElmer Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Horizon Diagnostics (United States).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Fluorescence in situ hybridization probe market by Type, Application and Region.

On the basis of geography, the market of Fluorescence in situ hybridization probe has been segmented into .

In January 2019, Oxford Gene Technology announced that it had received the US FDA's “de novo classification” for eight of its “Cytocell Aquarius Hematology Fluorescent In Situ Hybridization Probes (FISH)” that are specifically for acute myeloid Leukemia (AML) and myelodysplastic syndromes (AML) have developed MDS) applications. This leads to greater consumer acceptance of their products as the probes deliver high-quality results in less time. and In April 2018, Agilent Technologies, Inc. announced that it had added several offerings to its In-Situ Hybridization Probes that are compatible with its Dako Omnis product. They also announced that a manual IGFISH panel for use in lymphoma that is already CE-marked for in vitro diagnostics will be available to the European market. Using these probes in combination with Agilent's “Dako Omnis” improves results efficiency and increases the productivity of research laboratories.


Influencing Market Trend
  • Growing Adaption of the In-Vitro Diagnosis
  • Adoption of Advanced Technologies

Market Drivers
  • Growing Prevalence of Genetic Disorders
  • Increase in the Number of Chronic Disease Occurrence
  • Rising Prevalence of Breast Cancer

Opportunities
  • Government Initiatives to Support the R & D

Restraints
  • High Cost of the Technique
  • Existence of Variations in The Regulations for The Development and Usage of These Probes

Challenges
  • Absence of The Skilled Professionals to Interact and Utilize the Technology


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Fluorescence in situ hybridization probe, Venture Capitalists and Private Equity Firms and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.
Report Objectives / Segmentation Covered
By Type
  • RNA
  • DNA
By Application
  • Cancer Diagnosis
  • Genetic Disorders
  • Others
By End-User
  • Research Institutes
  • Diagnostic Centre
  • Biotechnology Companies
  • Companion Diagnostics
  • Academic Institutes

By Technique
  • Q- FISH
  • Flow- FISH

By Regions
    • 1. Market Overview
      • 1.1. Introduction
      • 1.2. Scope/Objective of the Study
        • 1.2.1. Research Objective
    • 2. Executive Summary
      • 2.1. Introduction
    • 3. Market Dynamics
      • 3.1. Introduction
      • 3.2. Market Drivers
        • 3.2.1. Growing Prevalence of Genetic Disorders
        • 3.2.2. Increase in the Number of Chronic Disease Occurrence
        • 3.2.3. Rising Prevalence of Breast Cancer
      • 3.3. Market Challenges
        • 3.3.1. Absence of The Skilled Professionals to Interact and Utilize the Technology
      • 3.4. Market Trends
        • 3.4.1. Growing Adaption of the In-Vitro Diagnosis
        • 3.4.2. Adoption of Advanced Technologies
    • 4. Market Factor Analysis
      • 4.1. Porters Five Forces
      • 4.2. Supply/Value Chain
      • 4.3. PESTEL analysis
      • 4.4. Market Entropy
      • 4.5. Patent/Trademark Analysis
    • 5. Global Fluorescence in situ hybridization probe, by Type, Application, End-User and Technique (value and price ) (2015-2020)
      • 5.1. Introduction
      • 5.2. Global Fluorescence in situ hybridization probe (Value)
        • 5.2.1. Global Fluorescence in situ hybridization probe by: Type (Value)
          • 5.2.1.1. RNA
          • 5.2.1.2. DNA
        • 5.2.2. Global Fluorescence in situ hybridization probe by: Application (Value)
          • 5.2.2.1. Cancer Diagnosis
          • 5.2.2.2. Genetic Disorders
          • 5.2.2.3. Others
        • 5.2.3. Global Fluorescence in situ hybridization probe by: End-User (Value)
          • 5.2.3.1. Research Institutes
          • 5.2.3.2. Diagnostic Centre
          • 5.2.3.3. Biotechnology Companies
          • 5.2.3.4. Companion Diagnostics
          • 5.2.3.5. Academic Institutes
        • 5.2.4. Global Fluorescence in situ hybridization probe by: Technique (Value)
          • 5.2.4.1. Q- FISH
          • 5.2.4.2. Flow- FISH
      • 5.3. Global Fluorescence in situ hybridization probe (Price)
        • 5.3.1. Global Fluorescence in situ hybridization probe by: Type (Price)
    • 6. Fluorescence in situ hybridization probe: Manufacturers/Players Analysis
      • 6.1. Competitive Landscape
        • 6.1.1. Market Share Analysis
          • 6.1.1.1. Top 3
          • 6.1.1.2. Top 5
      • 6.2. Peer Group Analysis (2020)
      • 6.3. BCG Matrix
      • 6.4. Company Profile
        • 6.4.1. Abbott Laboratories (United States)
          • 6.4.1.1. Business Overview
          • 6.4.1.2. Products/Services Offerings
          • 6.4.1.3. Financial Analysis
          • 6.4.1.4. SWOT Analysis
        • 6.4.2. Abnova Corporation (Taiwan)
          • 6.4.2.1. Business Overview
          • 6.4.2.2. Products/Services Offerings
          • 6.4.2.3. Financial Analysis
          • 6.4.2.4. SWOT Analysis
        • 6.4.3. Agilent Technologies (United States)
          • 6.4.3.1. Business Overview
          • 6.4.3.2. Products/Services Offerings
          • 6.4.3.3. Financial Analysis
          • 6.4.3.4. SWOT Analysis
        • 6.4.4. Biocare Medical, LLC (United States)
          • 6.4.4.1. Business Overview
          • 6.4.4.2. Products/Services Offerings
          • 6.4.4.3. Financial Analysis
          • 6.4.4.4. SWOT Analysis
        • 6.4.5. Biosearch Technologies Inc. (United States)
          • 6.4.5.1. Business Overview
          • 6.4.5.2. Products/Services Offerings
          • 6.4.5.3. Financial Analysis
          • 6.4.5.4. SWOT Analysis
        • 6.4.6. F. Hoffmann-La Roche AG (Switzerland)
          • 6.4.6.1. Business Overview
          • 6.4.6.2. Products/Services Offerings
          • 6.4.6.3. Financial Analysis
          • 6.4.6.4. SWOT Analysis
        • 6.4.7. Genemed Biotechnologies (United States)
          • 6.4.7.1. Business Overview
          • 6.4.7.2. Products/Services Offerings
          • 6.4.7.3. Financial Analysis
          • 6.4.7.4. SWOT Analysis
        • 6.4.8. Life Science Technologies (India)
          • 6.4.8.1. Business Overview
          • 6.4.8.2. Products/Services Offerings
          • 6.4.8.3. Financial Analysis
          • 6.4.8.4. SWOT Analysis
        • 6.4.9. Oxford Gene Technologies (United Kingdom)
          • 6.4.9.1. Business Overview
          • 6.4.9.2. Products/Services Offerings
          • 6.4.9.3. Financial Analysis
          • 6.4.9.4. SWOT Analysis
        • 6.4.10. PerkinElmer Inc. (United States)
          • 6.4.10.1. Business Overview
          • 6.4.10.2. Products/Services Offerings
          • 6.4.10.3. Financial Analysis
          • 6.4.10.4. SWOT Analysis
    • 7. Global Fluorescence in situ hybridization probe Sale, by Type, Application, End-User and Technique (value and price ) (2021-2026)
      • 7.1. Introduction
      • 7.2. Global Fluorescence in situ hybridization probe (Value)
        • 7.2.1. Global Fluorescence in situ hybridization probe by: Type (Value)
          • 7.2.1.1. RNA
          • 7.2.1.2. DNA
        • 7.2.2. Global Fluorescence in situ hybridization probe by: Application (Value)
          • 7.2.2.1. Cancer Diagnosis
          • 7.2.2.2. Genetic Disorders
          • 7.2.2.3. Others
        • 7.2.3. Global Fluorescence in situ hybridization probe by: End-User (Value)
          • 7.2.3.1. Research Institutes
          • 7.2.3.2. Diagnostic Centre
          • 7.2.3.3. Biotechnology Companies
          • 7.2.3.4. Companion Diagnostics
          • 7.2.3.5. Academic Institutes
        • 7.2.4. Global Fluorescence in situ hybridization probe by: Technique (Value)
          • 7.2.4.1. Q- FISH
          • 7.2.4.2. Flow- FISH
      • 7.3. Global Fluorescence in situ hybridization probe (Price)
        • 7.3.1. Global Fluorescence in situ hybridization probe by: Type (Price)
    • 8. Appendix
      • 8.1. Acronyms
    • 9. Methodology and Data Source
      • 9.1. Methodology/Research Approach
        • 9.1.1. Research Programs/Design
        • 9.1.2. Market Size Estimation
        • 9.1.3. Market Breakdown and Data Triangulation
      • 9.2. Data Source
        • 9.2.1. Secondary Sources
        • 9.2.2. Primary Sources
      • 9.3. Disclaimer
    List of Tables
    • Table 1. Fluorescence in situ hybridization probe: by Type(USD Million)
    • Table 2. Fluorescence in situ hybridization probe: by Application(USD Million)
    • Table 3. Fluorescence in situ hybridization probe: by End-User(USD Million)
    • Table 4. Fluorescence in situ hybridization probe: by Technique(USD Million)
    • Table 5. Fluorescence in situ hybridization probe: by Type(USD/Units)
    • Table 6. Company Basic Information, Sales Area and Its Competitors
    • Table 7. Company Basic Information, Sales Area and Its Competitors
    • Table 8. Company Basic Information, Sales Area and Its Competitors
    • Table 9. Company Basic Information, Sales Area and Its Competitors
    • Table 10. Company Basic Information, Sales Area and Its Competitors
    • Table 11. Company Basic Information, Sales Area and Its Competitors
    • Table 12. Company Basic Information, Sales Area and Its Competitors
    • Table 13. Company Basic Information, Sales Area and Its Competitors
    • Table 14. Company Basic Information, Sales Area and Its Competitors
    • Table 15. Company Basic Information, Sales Area and Its Competitors
    • Table 16. Fluorescence in situ hybridization probe: by Type(USD Million)
    • Table 17. Fluorescence in situ hybridization probe: by Application(USD Million)
    • Table 18. Fluorescence in situ hybridization probe: by End-User(USD Million)
    • Table 19. Fluorescence in situ hybridization probe: by Technique(USD Million)
    • Table 20. Fluorescence in situ hybridization probe: by Type(USD/Units)
    • Table 21. Research Programs/Design for This Report
    • Table 22. Key Data Information from Secondary Sources
    • Table 23. Key Data Information from Primary Sources
    List of Figures
    • Figure 1. Porters Five Forces
    • Figure 2. Supply/Value Chain
    • Figure 3. PESTEL analysis
    • Figure 4. Global Fluorescence in situ hybridization probe: by Type USD Million (2015-2020)
    • Figure 5. Global Fluorescence in situ hybridization probe: by Application USD Million (2015-2020)
    • Figure 6. Global Fluorescence in situ hybridization probe: by End-User USD Million (2015-2020)
    • Figure 7. Global Fluorescence in situ hybridization probe: by Technique USD Million (2015-2020)
    • Figure 8. Global Fluorescence in situ hybridization probe: by Type USD/Units (2015-2020)
    • Figure 9. Global Fluorescence in situ hybridization probe share by Players 2020 (%)
    • Figure 10. Global Fluorescence in situ hybridization probe share by Players (Top 3) 2020(%)
    • Figure 11. Global Fluorescence in situ hybridization probe share by Players (Top 5) 2020(%)
    • Figure 12. BCG Matrix for key Companies
    • Figure 13. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
    • Figure 14. Abbott Laboratories (United States) Revenue: by Geography 2020
    • Figure 15. Abnova Corporation (Taiwan) Revenue, Net Income and Gross profit
    • Figure 16. Abnova Corporation (Taiwan) Revenue: by Geography 2020
    • Figure 17. Agilent Technologies (United States) Revenue, Net Income and Gross profit
    • Figure 18. Agilent Technologies (United States) Revenue: by Geography 2020
    • Figure 19. Biocare Medical, LLC (United States) Revenue, Net Income and Gross profit
    • Figure 20. Biocare Medical, LLC (United States) Revenue: by Geography 2020
    • Figure 21. Biosearch Technologies Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 22. Biosearch Technologies Inc. (United States) Revenue: by Geography 2020
    • Figure 23. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
    • Figure 24. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2020
    • Figure 25. Genemed Biotechnologies (United States) Revenue, Net Income and Gross profit
    • Figure 26. Genemed Biotechnologies (United States) Revenue: by Geography 2020
    • Figure 27. Life Science Technologies (India) Revenue, Net Income and Gross profit
    • Figure 28. Life Science Technologies (India) Revenue: by Geography 2020
    • Figure 29. Oxford Gene Technologies (United Kingdom) Revenue, Net Income and Gross profit
    • Figure 30. Oxford Gene Technologies (United Kingdom) Revenue: by Geography 2020
    • Figure 31. PerkinElmer Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 32. PerkinElmer Inc. (United States) Revenue: by Geography 2020
    • Figure 33. Global Fluorescence in situ hybridization probe: by Type USD Million (2021-2026)
    • Figure 34. Global Fluorescence in situ hybridization probe: by Application USD Million (2021-2026)
    • Figure 35. Global Fluorescence in situ hybridization probe: by End-User USD Million (2021-2026)
    • Figure 36. Global Fluorescence in situ hybridization probe: by Technique USD Million (2021-2026)
    • Figure 37. Global Fluorescence in situ hybridization probe: by Type USD/Units (2021-2026)
    Some of the key companies/manufacturers profiled in the report
    • Abbott Laboratories (United States)
    • Abnova Corporation (Taiwan)
    • Agilent Technologies (United States)
    • Biocare Medical, LLC (United States)
    • Biosearch Technologies Inc. (United States)
    • F. Hoffmann-La Roche AG (Switzerland)
    • Genemed Biotechnologies (United States)
    • Life Science Technologies (India)
    • Oxford Gene Technologies (United Kingdom)
    • PerkinElmer Inc. (United States)
    Additional players considered in the study are as follows:
    Horizon Diagnostics (United States)
    Select License Type
    Sample Report Enquiry Before Buy Request Discount

    Speak with Analyst

    Want to find out more about this report?

    Get Free Consultation